MORGANTOWN, W.Va., April 24, 2013 (GLOBE NEWSWIRE) -- Protea Biosciences Group, Inc. ("Protea"), a leading bioanalytics company, announced today that Steve Turner, Protea's CEO, will present at the Needham & Company 12th Annual Healthcare Conference on April 30th, 12:50 PM ET, at the Westin Grand Central Hotel in New York City. Mr. Turner will present the Company's marketing of its groundbreaking LAESI technology platform, that enables researchers to generate comprehensive mass spectrometry imaging datasets on their tissue, cell or biofluid samples, for use in drug and biomarker discovery, without sample preparation.
"We are pleased to be invited to present at the prestigious Needham Healthcare Conference," stated Steve Turner, CEO. He added, "With our proprietary LAESI technology platform we can give our customers a whole new dimension in biomolecular analysis, mapping their compounds, such as drugs and metabolites, as they appear in tissues, even living cells and bacterial colonies."
LAESI technology was invented in the laboratory of Akos Vertes, PhD., Professor of Chemistry, George Washington University, and brought to market by Protea. LAESI (Laser Ablation Electrospray Ionization) technology allows two and three dimensional distribution profiling of biomolecules in biological samples for unambiguous drug / target interaction studies, as well as the study of bio-dynamics directly in living cells. Using LAESI mass spectrometry, multiple biomolecules can be mapped in a single analysis, providing comprehensive information on the different dynamics and biological processes underway in a cell sample.
The company recently completed the installation of LAESI instrumentation at the Waters Corp (NYSE:WAT) Waters MS Technology Centre located in Manchester, England, where researchers visiting the Waters Customer Center can experience first hand the LAESI DP-1000 instrument platform.
A replay of the presentation will be available at: www.proteabio.com on April 30.
More information about the upcoming conference can be found at: http://www.needhamco.com/Default/InstitutionalSalesAndTrading/Conferences.aspx.
About Protea Biosciences Group, Inc.
Protea is the leading developer and marketer of mass spectrometry imaging technologies that are focused on delivering revolutionary information for pharmaceutical and medical research applications that improve efficiency and outcomes.
This press release may contain certain statements relating to future results, which are forward looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's financial results, are contained in the Company's filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
CONTACT: Protea Biosciences, Inc., 955 Hartman Run Road, Morgantown, WV 26507 Phone: 304.292.2226 Fax: 304.292.7101 firstname.lastname@example.org www.proteabio.com IR Contact: Jeff Ramson, ProActive Capital Group 646-863-6341 email@example.com
Source:Protea Biosciences, Inc.